FLECAINIDE ACETATE Drug Patent Profile

When do Flecainide Acetate patents expire, and what generic alternatives are available?

Flecainide Acetate is a drug marketed by Amneal Pharm, Ani Pharms, Aurobindo Pharma Ltd, Chartwell, Hikma, Regcon Holdings, Sun Pharm Inds Ltd, and Yichang Humanwell. and is included in nine NDAs.

The generic ingredient in FLECAINIDE ACETATE is flecainide acetate. There are ten drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the flecainide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Flecainide Acetate

A generic version of FLECAINIDE ACETATE was approved as flecainide acetate by AMNEAL PHARM on July 31^st, 2001.

Summary for FLECAINIDE ACETATE

US Patents:	0
Applicants:	8
NDAs:	9

US Patents and Regulatory Information for FLECAINIDE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharm	FLECAINIDE ACETATE	flecainide acetate	TABLET;ORAL	075442-001	Jul 31, 2001	AB	RX	No	No
Hikma	FLECAINIDE ACETATE	flecainide acetate	TABLET;ORAL	076278-003	Jan 14, 2003	AB	RX	No	Yes
Sun Pharm Inds Ltd	FLECAINIDE ACETATE	flecainide acetate	TABLET;ORAL	076421-003	Mar 28, 2003	AB	RX	No	No
Ani Pharms	FLECAINIDE ACETATE	flecainide acetate	TABLET;ORAL	076030-002	Oct 28, 2002		DISCN	No	No

Flecainide Acetate: Market Landscape and Patent Expirations

Last updated: February 19, 2026

Flecainide acetate is an antiarrhythmic drug, classified as a Class Ic agent, used to treat and prevent certain types of supraventricular and ventricular cardiac arrhythmias. The primary market for flecainide acetate is in cardiology, targeting conditions such as atrial fibrillation, atrial flutter, and supraventricular tachycardias. Its efficacy in rhythm control has maintained its position in clinical practice despite the development of newer antiarrhythmic agents.

What is the current patent status of flecainide acetate?

The original patents covering the composition of matter and primary therapeutic uses of flecainide acetate have long expired. Flecainide acetate was first approved by the U.S. Food and Drug Administration (FDA) in 1985. The foundational patents, which protected the molecule itself and its initial indications, would have expired in the early 2000s.

• Composition of Matter Patents: Expired. These are the most significant patents protecting the drug molecule itself.
• Primary Use Patents: Expired. Patents covering the initial approved uses for treating arrhythmias.

While the core patents have expired, pharmaceutical companies may hold secondary patents. These could relate to:

• New Formulations: Patents on modified release formulations, different salt forms, or delivery mechanisms. For example, extended-release formulations could offer a distinct patent life.
• New Indications: Patents on novel uses of flecainide acetate discovered post-approval, although significant new indications for older drugs are less common.
• Manufacturing Processes: Patents on specific, efficient, or novel methods of synthesizing or purifying flecainide acetate. These are often less impactful on market exclusivity compared to composition or use patents.

As of the most recent patent landscape analysis, there are no active U.S. patents covering the basic composition of matter or primary approved uses of flecainide acetate that would prevent generic competition for these established indications [1].

Who are the key manufacturers and generic competitors?

The market for flecainide acetate is characterized by the presence of both branded and numerous generic manufacturers. The expiration of foundational patents has facilitated the entry of multiple generic players, leading to price competition.

Branded Manufacturer (Historical/Current):

• 3M Pharmaceuticals (now part of AbbVie): Historically marketed flecainide acetate under the brand name Tambocor. While the brand may still exist in some markets, the primary competitive landscape is now dominated by generics.

Key Generic Manufacturers (U.S. Market):

• Teva Pharmaceuticals: A major global generic pharmaceutical company with a presence in the flecainide acetate market.
• Apotex Inc.: Another significant player in the generic drug industry, supplying flecainide acetate.
• Breckenridge Pharmaceutical, Inc.: A U.S.-based generic manufacturer.
• Carlsbad Pharmaceuticals: Offers generic flecainide acetate.
• Various other smaller generic producers and contract manufacturers.

The availability of multiple generic options exerts downward pressure on pricing, making cost-effectiveness a primary driver for purchasers, such as hospitals and pharmacies.

What is the market size and growth potential for flecainide acetate?

The market for flecainide acetate is mature, driven by its established therapeutic role rather than rapid growth. Its market size is primarily defined by its use in treating chronic and episodic cardiac arrhythmias.

• Market Size: Estimating the precise global market size for flecainide acetate is challenging due to fragmented generic sales data. However, industry reports suggest the global market for antiarrhythmic drugs, of which flecainide is a component, is valued in the billions of dollars annually. Flecainide acetate specifically contributes a segment of this, likely in the hundreds of millions of dollars range globally.
• Growth Drivers:
  • Aging Population: The increasing prevalence of age-related cardiovascular conditions, such as atrial fibrillation, supports continued demand.
  • Clinical Guidelines: Flecainide acetate remains recommended in current clinical guidelines for specific arrhythmia management, particularly in patients without structural heart disease [2].
  • Cost-Effectiveness: As a generic drug, its affordability makes it an attractive option compared to newer, branded antiarrhythmics.
• Market Restraints:
  • Side Effect Profile: Flecainide acetate carries a risk of proarrhythmic effects, particularly in patients with underlying structural heart disease, leading to contraindications and careful patient selection [3].
  • Competition from Other Antiarrhythmics: Newer agents and non-pharmacological interventions (e.g., catheter ablation) compete for patients requiring arrhythmia management.
  • Limited New Indications: The lack of significant new therapeutic indications for flecainide acetate limits opportunities for market expansion beyond its established uses.

The market is expected to grow at a low single-digit compound annual growth rate (CAGR), reflecting its stable, albeit mature, demand profile.

What are the key therapeutic indications and patient populations?

Flecainide acetate is indicated for the prophylaxis of supraventricular tachycardia (SVT) and for the maintenance of normal sinus rhythm in patients with atrial fibrillation (AF) or atrial flutter. It is also used for the prevention of documented, life-threatening ventricular arrhythmias.

Key Indications:

• Atrial Fibrillation (AF): Used for rhythm control to maintain normal sinus rhythm. This is a common indication.
• Atrial Flutter: Similar to AF, used to restore and maintain sinus rhythm.
• Supraventricular Tachycardias (SVT): Including atrioventricular nodal reentrant tachycardia and atrioventricular reentrant tachycardia associated with an extra pathway.
• Ventricular Arrhythmias: Reserved for patients with documented symptomatic, sustained ventricular tachycardia or ventricular fibrillation that is life-threatening and has not responded to other therapies.

Patient Populations & Considerations:

• Patients without Structural Heart Disease: Flecainide is most safely used in patients with normal left ventricular function and without significant structural heart disease.
• Patients with Symptomatic Arrhythmias: Individuals experiencing disruptive symptoms such as palpitations, dizziness, or syncope due to their arrhythmias.
• Contraindicated Populations: Patients with known hypersensitivity to flecainide, prior history of myocardial infarction or heart failure, or significant left ventricular dysfunction are generally contraindicated due to the risk of proarrhythmia and negative inotropic effects [3].

The precise dosage and suitability of flecainide acetate are determined by electrophysiologists and cardiologists based on the specific arrhythmia, patient comorbidities, and risk assessment.

What is the competitive landscape for antiarrhythmic drugs?

Flecainide acetate operates within a broader competitive landscape of antiarrhythmic medications and alternative treatment modalities. This competition influences its market share and pricing.

Classes of Antiarrhythmic Drugs:

• Class I (Sodium Channel Blockers):
  • Class Ia: Quinidine, Procainamide, Disopyramide. (Less commonly used now due to side effect profiles).
  • Class Ib: Lidocaine, Mexiletine. (Primarily for ventricular arrhythmias).
  • Class Ic: Flecainide, Propafenone. (Flecainide and Propafenone are the most prominent in this class for supraventricular arrhythmias).
• Class II (Beta-Blockers): Metoprolol, Atenolol, Propranolol. (Widely used for rate control in AF and as a first-line therapy for many arrhythmias).
• Class III (Potassium Channel Blockers): Amiodarone, Dronedarone, Sotalol, Ibutilide. (Amiodarone is a broad-spectrum agent, Dronedarone is a less toxic alternative for AF).
• Class IV (Calcium Channel Blockers): Verapamil, Diltiazem. (Primarily for rate control in AF and SVT).

Alternative Therapies:

• Catheter Ablation: A curative procedure for many supraventricular arrhythmias and increasingly for AF. It represents a significant alternative to long-term antiarrhythmic drug therapy.
• Anticoagulation: For patients with atrial fibrillation, preventing stroke is paramount. Anticoagulants (e.g., warfarin, direct oral anticoagulants like apixaban, rivaroxaban) are essential, and their use often coexists with or precedes the need for rhythm control.
• Lifestyle Modifications & Device Therapy: Pacemakers and implantable cardioverter-defibrillators (ICDs) are crucial for certain types of arrhythmias.

Flecainide's Position: Flecainide acetate is a well-established and effective choice for rhythm control, particularly in patients without structural heart disease. However, it faces competition from:

• Propafenone: Another Class Ic agent with a similar efficacy and safety profile for SVT and AF.
• Beta-Blockers and Calcium Channel Blockers: Often used for rate control and as initial management steps.
• Amiodarone: A potent option but with a more complex side effect profile.
• Catheter Ablation: As a potentially curative option, it is increasingly preferred for eligible patients.

The choice of therapy is highly individualized, considering efficacy, safety, patient comorbidities, and patient preference.

What is the regulatory status and potential for new developments?

The regulatory status of flecainide acetate is well-established, with its approval for the specified indications by major regulatory bodies like the FDA in the U.S. and the European Medicines Agency (EMA) in Europe.

• FDA Status: Approved for use as a prescription drug.
• EMA Status: Approved in European Union member states.

Potential for New Developments:

Given its long history and generic status, significant new developments for flecainide acetate are unlikely.

• New Formulations: While historically possible, the development of novel, patentable formulations of older generic drugs is an infrequent strategy. The cost and time investment for such development would need to be justified by a clear market advantage or a significant improvement in patient outcomes that differentiates it substantially from existing generic options.
• New Indications: Discovering and gaining regulatory approval for entirely new indications for a drug with a well-defined mechanism and safety profile like flecainide is rare. The extensive clinical trials required would be a substantial undertaking.
• Manufacturing Process Improvements: Companies may continuously seek to optimize manufacturing processes for efficiency and cost reduction, but these are typically proprietary improvements rather than patentable innovations that create new market exclusivity.

The future of flecainide acetate is predominantly tied to its existing market and the ongoing need for cost-effective antiarrhythmic therapy, rather than the introduction of novel therapeutic applications or formulations.

Key Takeaways

• Patent Expiration: Foundational patents for flecainide acetate have expired, allowing for widespread generic manufacturing and distribution. No significant patent barriers exist for its primary indications.
• Market Maturity: The flecainide acetate market is mature, with stable demand driven by its efficacy in treating cardiac arrhythmias.
• Generic Dominance: The market is dominated by generic manufacturers, leading to competitive pricing and a focus on cost-effectiveness.
• Therapeutic Niche: Flecainide acetate remains a valuable option for rhythm control, particularly in patients without structural heart disease, as supported by clinical guidelines.
• Competition: It competes with other antiarrhythmic drug classes (beta-blockers, potassium channel blockers) and increasingly with non-pharmacological interventions like catheter ablation.
• Limited Innovation Potential: Significant future growth or market expansion is unlikely due to its generic status and the lack of new indications or highly differentiated formulations on the horizon.

Frequently Asked Questions

• Q1: Are there any upcoming patent expiries that could impact the flecainide acetate market? No, the core composition of matter and primary use patents for flecainide acetate have expired. Any remaining secondary patents are unlikely to create new market exclusivity for its established uses.
• Q2: What is the primary risk associated with prescribing flecainide acetate? The primary risk is proarrhythmia, meaning it can induce new or worsen existing arrhythmias, especially in patients with underlying structural heart disease or impaired cardiac function.
• Q3: How does flecainide acetate compare to propafenone in terms of efficacy and safety? Flecainide acetate and propafenone are both Class Ic antiarrhythmics with similar efficacy profiles for supraventricular arrhythmias. They share similar proarrhythmic risks and contraindications.
• Q4: Is catheter ablation a viable alternative to flecainide acetate for atrial fibrillation management? Yes, catheter ablation is a widely used and often curative treatment option for atrial fibrillation, particularly for symptomatic patients who have not responded to or are intolerant of antiarrhythmic drugs like flecainide.
• Q5: What are the long-term sales projections for flecainide acetate? Long-term sales are projected to remain stable with low single-digit annual growth, reflecting its status as a mature, generic antiarrhythmic drug with consistent clinical utility.

---

Sources

[1] U.S. Food and Drug Administration. (2023). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA website] (Specific URL would be to the Orange Book search function, which is dynamic. General reference to the resource is appropriate here.)

[2] Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., ... & Schotten, U. (2020). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed by the European Society of Cardiology (ESC) on behalf of the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). European Heart Journal, 42(5), 373-498.

[3] U.S. Food and Drug Administration. (n.d.). Flecainide Acetate Tablets Prescribing Information. Retrieved from [FDA website] (Specific URL would be to the drug label database, which is dynamic. General reference to the resource is appropriate here.)